Here are the S-3 shelf registrations from Dianthus Therapeutics, Inc. (DNTH) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow DNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNTH filings page.
Dianthus Therapeutics, Inc. (DNTH) has filed an automatic shelf registration on Form S-3 as a well-known seasoned issuer and, under it, established an at-the-market offering program to sell up to $500,000,000 of common stock through TD Cowen. The base shelf also permits future offerings of an indeterminate amount of common stock, preferred stock, debt securities, warrants and units. Common stock outstanding was 54,798,338 shares as of June 30, 2026, and the last reported price was $101.12 per share on September 17, 2026. The company intends to use proceeds primarily to fund preclinical and clinical development, along with working capital and other general corporate purposes, with potential use for in-licensing or acquiring product candidates.
Dianthus Therapeutics, Inc. is registering up to $600,000,000 of securities that it may offer over time. The shelf registration covers common stock, preferred stock, debt securities, warrants and units, which can be issued in one or more offerings with terms set in future prospectus supplements.
Dianthus is a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases, led by its monoclonal antibody candidate claseprubart, designed to target the active form of the C1s complement protein. The company’s common stock trades on The Nasdaq Capital Market under the symbol “DNTH,” and the last reported sale price on January 27, 2026 was $50.31 per share.
The company expects to use net proceeds from any future sales primarily to fund preclinical and clinical development, working capital and general corporate purposes, and potentially to license, acquire or invest in additional product candidates.